Keywords: Hemophilia A; Factor VIII inhibitor; Inhibitor by passing activity; Activated prothrombin concentrate; Recombinant activated factor VII; Factor VIII; Novel agents; TFPI antagonists; ATIII antagonist; Concizumab; Emicizumab; Alpha 1 antitrypsin;